These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Seidu S; Kunutsor SK; Topsever P; Khunti K Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161 [TBL] [Abstract][Full Text] [Related]
30. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies. Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118 [TBL] [Abstract][Full Text] [Related]
31. Impact of Sodium-Glucose Co-Transporter 2 Inhibitors on Cardiac Protection. Wu VC; Li YR; Wang CY Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281221 [TBL] [Abstract][Full Text] [Related]
32. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242 [TBL] [Abstract][Full Text] [Related]
33. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Garcia-Ropero A; Badimon JJ; Santos-Gallego CG Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454 [TBL] [Abstract][Full Text] [Related]
34. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. Lan NSR; Fegan PG; Yeap BB; Dwivedi G ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic Interventions of Novel SGLT2 Inhibitors Against Metabolic Disorders: Transforming the Association into Perspectives. Irshad K; Akash MSH; Rehman K; Sharif H Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2169-2180. PubMed ID: 34139987 [TBL] [Abstract][Full Text] [Related]
36. SGLT-2 inhibitors in diabetes: a focus on renoprotection. Gonzalez DE; Foresto RD; Ribeiro AB Rev Assoc Med Bras (1992); 2020 Jan; 66Suppl 1(Suppl 1):s17-s24. PubMed ID: 31939531 [TBL] [Abstract][Full Text] [Related]
37. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease. Mima A J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432 [TBL] [Abstract][Full Text] [Related]
38. SGLT2 Inhibitors and Their Antiarrhythmic Properties. Kolesnik E; Scherr D; Rohrer U; Benedikt M; Manninger M; Sourij H; von Lewinski D Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163599 [TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis. Zhang XL; Zhu QQ; Chen YH; Li XL; Chen F; Huang JA; Xu B J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29353233 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]